top of page

Nutra Pharma Announces Nyloxin Acceptance by Chinese Medical Authority - CPAM

April 30, 2015

Nutra Pharma Has Announced That They Have Received Notification of the Acceptance of Nyloxin(R) by the China International Exchange and Promotive Association for Medical and Healthcare (CPAM)

CORAL SPRINGS, FL--(Marketwired - Apr 30, 2015) - Nutra Pharma Corporation (OTC: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they have received notification of the acceptance of Nyloxin® by the China International Exchange and Promotive Association for Medical and Healthcare (CPAM). This process was successfully conducted by the Vancouver Commodities Group (VCG) that had been hired by Nutra Pharma to begin the process of identifying and vetting potential distributors in China for the Company's Over-the-Counter pain drug, Nyloxin®.

"We only released the engagement of VCG last week and we've already seen some results from their efforts," stated Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. "We've received notification from the Vice-Chairman of CPAM, stating a positive review of Nyloxin and their willingness to aid us in the registration and distribution of our products throughout China," he continued. "The next steps will be to work with VCG and CPAM to identify and engage distributors in China. It is our goal to move this process forward expeditiously and grow sales in China at the same time as we are creating our first large orders for the India market," he concluded.

The China International Exchange and Promotive Association for Medical and Healthcare (CPAM) is a public welfare and non-profit agency governed by the Ministry of Health in China. One of CPAM's primary functions is to promote exchanges and cooperation in the healthcare industry between China and other countries. China is currently the world's most populous country with almost 1.4B people. According to Research & Markets, the analgesics drug category in China was worth $1.2 billion in 2014 and was dominated by Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and topical ointments.

The letter response to Nutra Pharma was signed by the Vice-Chairman of CPAM and stated, "Based on our review [of Nyloxin] we believe the Company's products have a very large potential in the market of the People's Republic of China, where our people suffer from the same kinds of disease-related pain as people in the USA experience." The letter went on to offer Nutra Pharma aid in developing relationships with Chinese companies for regulatory approval and distribution.

Nyloxin® is an over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. Nyloxin® is currently available as an oral spray for treating back pain, neck aches, headaches, joint pain, migraines, and neuralgia, and as a topical gel for treating joint pain, neck pain, arthritis pain, and pain from repetitive stress. In addition to its everyday strength formulation, Nyloxin® is also offered in an extra strength formula for more advanced, Stage 3, chronic pain.

About Nutra Pharma Corp.

Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. Additionally, the Company markets drug products for sale for the treatment of pain under the brand Nyloxin® and Pet Pain-Away.

For additional information about Nutra Pharma, visit: or

SEC Disclaimer

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The acceptance of Nyloxin by CPAM should not be construed as an indication in any way whatsoever of the future value of the Company's common stock or its financial value. The Company's filings may be accessed at the SEC's Edgar system at Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

  • Facebook Basic Square
  • Twitter Basic Square
  • Google+ Basic Square
bottom of page